News

US FDA approves PIMJETMI (pimicotinib) for tenosynovial giant cell tumour

What's the story? On 10 November 2026, the US Food and Drug Administration (FDA) approved pimicotinib — sold as PIMJETMI — for adults with symptomatic tenosynovial giant cell tumour (TGCT), a rare, usually non-cancerous growth in the lining of joints and tendons, in patients for whom surgical removal could cause worsening disability or serious complications. The drug was developed by Abbisko Therapeutics and is licensed and marketed in the US by EMD Serono, the American healthcare arm of Merck KGaADealroom has a profile for this one. Try Dealroom → of Germany.

Why it matters: PIMJETMI is a kinase inhibitor — a type of drug that blocks enzymes involved in cell signalling — that targets CSF1R, a protein that drives the tumour-forming cells in TGCT. It is a new oral, systemic option for patients whose options so far have largely been surgery or, in advanced disease, intravenous therapy. The approval is based on the global Phase III MANEUVER trial, in which patients took 50 mg once daily or placebo. At week 25, the objective response rate — the share of patients whose tumours shrank measurably — was 56% in the pimicotinib group versus 3.2% in the placebo group (p<0.0001). Median duration of response was not reached; 91% of responders held their response for at least 6 months and 77% for at least 12 months. Patients also showed statistically significant gains in joint movement, pain and physical function versus placebo. The most common side effects (over 20% of patients) included itching, rash, swelling of the face and around the eyes, fatigue, nausea, headache and swelling in the limbs.

Abbisko, which developed the drug, receives a milestone payment tied to the first US commercial sale plus double-digit royalties on US net sales under its licence agreement with Merck KGaA.

Read more: FDA, 10 November 2026 · Abbisko Therapeutics via PR Newswire, 10 November 2026

More top stories